Article
The Lipid Hydrolase ABHD6 is a Therapeutic Target in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)-Related Hepatocellular Carcinoma
2025-08-02
Abstract excerpt
Primary liver cancer accounts for approximately 700,000 deaths worldwide annually ranking third in cancer-related mortality, with hepatocellular carcinoma (HCC) comprising the majority of these tumors. Metabolic dysfunction-associated steatotic liver disease (MASLD) is currently a leading cause of HCC in the United States. We previously identified the lipid hydrolase alpha/beta hydrolase domain 6 (ABHD6) as a key...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- dfb62730-8361-5a81-aea0-9bc9f055b95e
- DOI
- 10.1101/2025.07.29.667509
